← Leaderboards
Christopher J Kemp
Fred Hutchinson Cancer Research Center
$19,551,750
Attributed
$20,889,546
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,889,546 · 8
By mechanism
U01$11,573,899 · 3
R01$9,139,647 · 4
R03$176,000 · 1
Top collaborators
- Bruce E Clurman6 shared
- Julia Sidorova6 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Margaret M Madeleine$13,649,862
- Bruce E Clurman$16,275,505
- Ying Qing Chen$12,344,940
- Ahmed Mohamed Diab$822,863
- Ann C Duerr$21,182,270
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorCellsClinical TrialsPharmaceutical PreparationsNeoplastic CellMalignant NeoplasmsSuccessGeneticMutantClinical OncologyComputational BiologyMutationDrug ResistanceTargeted TreatmentClinicResponseSamplingDrug DevelopmentScreeningSolid NeoplasmNew Therapeutic TargetGenomicsOrganoidsValidation
Grant awards (37)
A Patient-Centric Approach to Advance Functional Precision Oncology$1,060,954
U01 · FY2025 · CA · contact PI
A Patient-Centric Approach to Advance Functional Precision Oncology$1,007,878
U01 · FY2024 · CA · contact PI
A Patient-Centric Approach to Advance Functional Precision Oncology$1,098,796
U01 · FY2023 · CA · contact PI
Mechanisms of Pip4k2c and Pip5k1b dependencies in Ras driven squamous cell carcinoma$176,000
R03 · FY2023 · TR · contact PI
An Academic-Industry Partnership to Advance Functional Genomics for Personalized Oncology.$456,691
R01 · FY2022 · CA · contact PI
An Academic-Industry Partnership to Advance Functional Genomics for Personalized Oncology.$127,681
R01 · FY2022 · CA · contact PI
An Academic-Industry Partnership to Advance Functional Genomics for Personalized Oncology.$599,950
R01 · FY2021 · CA · contact PI
Personalized cancer models to discover and develop new therapeutic targets.$470,312
U01 · FY2021 · CA · contact PI
Personalized cancer models to discover and develop new therapeutic targets.$378,822
U01 · FY2021 · CA · contact PI
Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer$234,777
R01 · FY2021 · CA
Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer$166,708
R01 · FY2021 · CA
Personalized cancer models to discover and develop new therapeutic targets.$849,250
U01 · FY2020 · CA · contact PI
An Academic-Industry Partnership to Advance Functional Genomics for Personalized Oncology.$602,872
R01 · FY2020 · CA · contact PI
Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer$401,486
R01 · FY2020 · CA
Personalized cancer models to discover and develop new therapeutic targets.$821,431
U01 · FY2019 · CA · contact PI
An Academic-Industry Partnership to Advance Functional Genomics for Personalized Oncology.$588,045
R01 · FY2019 · CA · contact PI
Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer$389,319
R01 · FY2019 · CA
Personalized cancer models to discover and develop new therapeutic targets.$847,023
U01 · FY2018 · CA · contact PI
An Academic-Industry Partnership to Advance Functional Genomics for Personalized Oncology.$647,099
R01 · FY2018 · CA · contact PI
Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer$399,129
R01 · FY2018 · CA
Personalized cancer models to discover and develop new therapeutic targets.$902,672
U01 · FY2017 · CA · contact PI
Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer$415,275
R01 · FY2017 · CA
An integrated computational and functional genomics discovery engine for preclini$1,009,007
U01 · FY2016 · CA · contact PI
An integrated computational and functional genomics discovery engine for preclini$1,025,918
U01 · FY2015 · CA · contact PI
An integrated computational and functional genomics discovery engine for preclini$1,013,016
U01 · FY2014 · CA · contact PI
An integrated computational and functional genomics discovery engine for preclini$1,088,820
U01 · FY2013 · CA · contact PI
Mouse Models of Tumor Progression and Therapy Response$364,978
R01 · FY2007 · CA · contact PI
The Role of Double Strand Breaks in Carcinogenesis$375,879
R01 · FY2006 · CA · contact PI
Mouse Models of Tumor Progression and Therapy Response$375,879
R01 · FY2006 · CA · contact PI
Mouse Models of Tumor Progression and Therapy Response$384,925
R01 · FY2005 · CA
The Role of Double Strand Breaks in Carcinogenesis$384,925
R01 · FY2005 · CA
Mouse Models of Tumor Progression and Therapy Response$384,925
R01 · FY2004 · CA
The Role of Double Strand Breaks in Carcinogenesis$384,925
R01 · FY2004 · CA
Mouse Models of Tumor Progression and Therapy Response$384,925
R01 · FY2003 · CA
The Role of Double Strand Breaks in Carcinogenesis$384,925
R01 · FY2003 · CA
The Role of Double Strand Breaks in Carcinogenesis$380,377
R01 · FY2002 · CA
DOUBLE STRAND BREAKS AND CARCINOGENESIS$303,952
R01 · FY2000 · CA